BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 18061071)

  • 1. Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias: results from the TOVA study.
    Albert CM; Rosenthal L; Calkins H; Steinberg JS; Ruskin JN; Wang P; Muller JE; Mittleman MA;
    J Am Coll Cardiol; 2007 Dec; 50(23):2233-40. PubMed ID: 18061071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depression as a predictor for appropriate shocks among patients with implantable cardioverter-defibrillators: results from the Triggers of Ventricular Arrhythmias (TOVA) study.
    Whang W; Albert CM; Sears SF; Lampert R; Conti JB; Wang PJ; Singh JP; Ruskin JN; Muller JE; Mittleman MA;
    J Am Coll Cardiol; 2005 Apr; 45(7):1090-5. PubMed ID: 15808769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Zarraga IG; Dougherty CM; MacMurdy KS; Raitt MH
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):739-47. PubMed ID: 22773022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
    Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Haigney MC; Zareba W; Gentlesk PJ; Goldstein RE; Illovsky M; McNitt S; Andrews ML; Moss AJ;
    J Am Coll Cardiol; 2004 Oct; 44(7):1481-7. PubMed ID: 15464332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
    Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
    J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.
    Klein G; Lissel C; Fuchs AC; Gardiwal A; Oswald H; Desousa M; Pichlmaier AM; Lichtinghagen R; Geerlings H; Lippolt P; Niehaus M; Drexler H; Korte T
    Europace; 2006 Aug; 8(8):618-24. PubMed ID: 16864615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ;
    J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and relevance of clustering ventricular arrhythmias in defibrillator recipients.
    Stuber T; Eigenmann C; Delacrétaz E
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):702-7. PubMed ID: 16008807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: a DEFINITE substudy.
    Daubert JP; Winters SL; Subacius H; Berger RD; Ellenbogen KA; Taylor SG; Schaechter A; Howard A; Kadish A;
    Pacing Clin Electrophysiol; 2009 Jun; 32(6):755-61. PubMed ID: 19545338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
    Li CH; Lin YJ; Huang JL; Wu TJ; Cheng CC; Lin WS; Tuan TC; Chang SL; Lo LW; Hu YF; Chao TF; Chung FP; Tsai CF; Tsao HM; Chen SA
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):750-6. PubMed ID: 22353378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial.
    Wilkoff BL; Ousdigian KT; Sterns LD; Wang ZJ; Wilson RD; Morgan JM;
    J Am Coll Cardiol; 2006 Jul; 48(2):330-9. PubMed ID: 16843184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (HeartMate II).
    Andersen M; Videbaek R; Boesgaard S; Sander K; Hansen PB; Gustafsson F
    J Heart Lung Transplant; 2009 Jul; 28(7):733-5. PubMed ID: 19560703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators.
    Ermis C; Seutter R; Zhu AX; Benditt LC; VanHeel L; Sakaguchi S; Lurie KG; Lu F; Benditt DG
    J Am Coll Cardiol; 2005 Dec; 46(12):2258-63. PubMed ID: 16360055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term incidence of malignant ventricular arrhythmia and shock therapy in patients with primary defibrillator implantation does not differ from event rates in patients treated for survived cardiac arrest.
    Backenköhler U; Erdogan A; Steen-Mueller MK; Kuhlmann C; Most A; Schaefer C; Stertmann W; Waas W; Tillmanns H; Waldecker B
    J Cardiovasc Electrophysiol; 2005 May; 16(5):478-82. PubMed ID: 15877617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of interleukin-6 and the risk of malignant ventricular tachyarrhythmia in ICD-recipients--a pilot study.
    Streitner F; Kuschyk J; Veltmann C; Brueckmann M; Streitner I; Brade J; Neumaier M; Bertsch T; Schumacher B; Borggrefe M; Wolpert C
    Cytokine; 2007 Oct; 40(1):30-4. PubMed ID: 17851087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of first ventricular tachycardia cycle length on rate of ventricular arrhythmia recurrence in patients with implantable cardioverter-defibrillator.
    Arya A; Haghjoo M; Nikoo MH; Dehghani MR; Fazelifar AF; Sadr-Ameli MA
    J Electrocardiol; 2006 Oct; 39(4):404-8. PubMed ID: 16895771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.